BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20332683)

  • 1. [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
    Yagi M; Watanabe S; Yoshino S; Hazama S; Suga T; Nakazawa S
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):457-62. PubMed ID: 20332683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lentinan combination therapy for unresectable advanced gastric cancer.
    Higashi D; Seki K; Ishibashi Y; Egawa Y; Koga M; Sasaki T; Hirano K; Mikami K; Futami K; Maekawa T; Sudo M
    Anticancer Res; 2012 Jun; 32(6):2365-8. PubMed ID: 22641676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer.
    Hazama S; Watanabe S; Ohashi M; Yagi M; Suzuki M; Matsuda K; Yamamoto T; Suga Y; Suga T; Nakazawa S; Oka M
    Anticancer Res; 2009 Jul; 29(7):2611-7. PubMed ID: 19596936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer.
    Shimizu K; Watanabe S; Watanabe S; Matsuda K; Suga T; Nakazawa S; Shiratori K
    Hepatogastroenterology; 2009; 56(89):240-4. PubMed ID: 19453066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer.
    Yoshino S; Watanabe S; Imano M; Suga T; Nakazawa S; Hazama S; Oka M
    Hepatogastroenterology; 2010; 57(97):172-7. PubMed ID: 20422897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy of S-1/low-dose CDDP/lentinan for advanced gastric cancer].
    Hori T; Ikehara T; Takatsuka S; Fukuoka T; Tendo M; Tezuka K; Dan N; Nishino H; Hirakawa K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):293-5. PubMed ID: 21368498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
    Nimura H; Mitsumori N; Tsukagoshi S; Nakajima M; Atomi Y; Suzuki S; Kusano M; Yoshiyuki T; Tokunaga A
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1289-96. PubMed ID: 14518408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TS-1/CDDP/Lentinan combination chemotherapy for inoperable advanced gastric cancer].
    Nagahashi S; Suzuki H; Nishiwaki M; Okuda K; Kurosawa Y; Terada S; Sugihara T; Andou K; Hibi T
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):1999-2003. PubMed ID: 15570928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer].
    Nimura H; Mitsumori N; Takahashi N; Kashimura H; Takayama S; Kashiwagi H; Yanaga K
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():106-9. PubMed ID: 16897983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
    Ohshima T; Yamada R; Hatori S; Kunisaki C; Makino T; Yamazaki Y; Suda T; Rino Y; Takanashi Y; Imada T
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1105-10. PubMed ID: 16912529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
    Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
    Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.
    Yamanaka T; Matsumoto S; Teramukai S; Ishiwata R; Nagai Y; Fukushima M
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):335-43. PubMed ID: 17922276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
    Yamamura Y; Kodera Y; Tanemura H; Oshita H; Miyashita K; Fujimura T;
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):361-5. PubMed ID: 15045941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
    Koizumi W; Akiya T; Sato A; Sakuyama T; Sasaki E; Tomidokoro T; Hamada T; Fujimori M; Kikuchi Y; Shimada K; Mine T; Yamaguchi K; Sasaki T; Kurihara M
    Cancer Chemother Pharmacol; 2010 May; 65(6):1093-9. PubMed ID: 19727730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
    Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
    Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TS-1 and lentinan combination immunochemotherapy for advanced or recurrent gastric cancer: a preliminary report].
    Kimura Y; Iijima S; Kato T; Tsujie M; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E; Matsuura N; Kikkawa N
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1791-3. PubMed ID: 14619521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new regimen for TS-1 therapy designed to minimize adverse reactions by introducing a one-week interval after each two-week dosing session].
    Kimura Y; Kikkawa N; Iijima S; Kato T; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1403-9. PubMed ID: 12214468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.